Last Call

Naturalistic Self-Blinding Microdose Study

Dear community,

The self-blinding microdose study team, led by Dr. Balázs Szigeti and Dr. David Erritzoe of Imperial College London, in partnership with Amanda Feilding of the Beckley Foundation, would like to give you another short update about the latest developments around the project.

If you want to know more about this project and its background then read the previous update and the original announcement. You can also read more about microdosing research here.

After expanding the study protocol to include plant-based psychedelics and support for volumetric dosing, we have another addition to make joining this study easier than ever before. Our friends from the Netherlands microdosing community are selling ready-made ‘self-blinding’ kits. This contains everything you need for the study (envelopes, zip bags, etc.), everything except the drug.

 

Phase 1 of data collection will close at the end of 2019, so the last valid start date is 25 November 2019. Data collected during phase 1 will be analysed and published in a scientific journal Q1 of 2020. The study will remain open after phase 1. and data collected in phase 2 may be published later when enough new data has been collected.

Dr. Balázs Szigeti has been touring the US and Canada to give talks about the study in front of psychedelic societies but you can watch his talk from New York in the video below!

Thank you for your continued support, we cannot wait to share the results with you!

Kind regards,

David Erritzoe, Balazs Szigeti, David Nutt, Robin Carhart-Harris, and Amanda Feilding

To register for the study, or for any more information, please visit:
http://selfblinding-microdose.org/.

Contact:
microdose-study@protonmail.com

Please do not contact us asking to provide you with psychedelics or any other drugs. This observational study is only eligible for people that are currently, or are planning to start, microdosing on their own initiative with their own existing supply of blotter-based psychedelics.